Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
about
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1Current and future trials of targeted therapies in cutaneous melanomaNew tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeuticsSorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CAPhase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.Angiogenesis inhibitors in the treatment of prostate cancer.Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.New knowledge of the mechanisms of sorafenib resistance in liver cancer20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicinNutlin-3 enhances sorafenib efficacy in renal cell carcinomaPhase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Current concepts of metastasis in melanoma.Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.Targeting angiogenesis in metastatic breast cancerMechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.Sorafenib for treatment of hepatocellular carcinoma: a systematic review.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programTargeting the MAPK pathway in melanoma: why some approaches succeed and other fail.Latest developments in targeted therapy for hepatocellular carcinoma.Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.Sorafenib in locally advanced or metastatic breast cancer.Systemic therapies in hepatocellular carcinoma: present and future.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.Pediatric hepatocellular carcinoma: challenges and solutions.Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.NMR-Based Metabolic Profiling Reveals Neurochemical Alterations in the Brain of Rats Treated with Sorafenib.Changes in tumor oxygen state after sorafenib therapy evaluated by 18F-fluoromisonidazole hypoxia imaging of renal cell carcinoma xenograftsSorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials.Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transportersA phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
P2860
Q24655144-90D624C3-778F-43C2-A7DC-1773535A4105Q27022355-29611769-E404-4C27-81C2-08988379468DQ30371980-055F71FB-88B8-4660-AF41-31CC571FA946Q30528973-8D22CAAB-15D5-4CD1-B30C-D29DFC6445D8Q33395884-0C42F3E7-4548-4D32-9891-46BAF0BF65C1Q33413701-355A230D-194F-474D-BC2C-D0F33E7CF1B8Q33611121-48F19E49-89F1-41F4-BE93-45DC1E3827B6Q33620083-62F51F2D-63CB-4E39-AD13-DEDCE624D034Q33759933-5465280E-014C-40F3-8AA6-670C0D01DF73Q34101000-EED70694-76AA-4F9B-9149-BF8FC0104463Q34127380-5290C751-B36F-4BE7-B121-33AA7D6217E7Q34200743-31B25648-2E97-427B-AD7C-00E838D19EB3Q34307356-8F042E65-149A-426F-A3B4-86DB21E8D125Q34610427-A93EF928-44DA-4A7A-AC0F-3DD021206F94Q34678882-F7288211-1B7B-45EA-9437-E18C6C7FB9B0Q35023711-CD3E79DA-95A7-4F9B-AED8-81FCE0DB3332Q35691891-5D1A93EF-583F-4F58-8F73-6579B229A615Q36182795-7304C1AB-42E6-4D16-B897-4839FCB185CEQ36500021-1B0C46B8-2C9B-44E1-B0C1-C9268BBDCAB7Q36680204-60C140D6-C2A8-43F7-A100-1E49E006B6CFQ37227994-BE17BE09-B6CC-4A17-9C86-9D6D5476B79EQ37295112-29854D46-7346-439A-991B-F59F07322897Q37745182-7E30AFE3-E1F9-4B39-8655-B96935A0E976Q37799829-435F9E62-9163-432F-8727-2145451A687DQ37827878-AEFC88F9-5A4D-4383-8D17-C5B24FDA64C5Q38012156-30AB98CD-D925-43E4-867C-733C0637EAFDQ38150875-C0CBCB84-700E-42F8-8004-5F8FD745E158Q38322346-194D5134-8132-4132-A961-2F16462F6D7CQ38725757-719451C4-CC9A-4C3E-AA45-7B920484B28EQ38987929-6E95760A-BF06-4854-A86B-C4BAA01BD14CQ39016415-8A7E590A-5F8C-4778-8FA5-9B9135A19832Q39211391-ACBDE11D-BCC0-4A58-B574-2576AD45B54DQ39500664-EE3E5D3A-4E6F-4CB2-B184-1750AAE143F7Q39643630-23548FCA-B375-48C4-9B03-E36D5CE54DBCQ40669763-0FAA5992-DA9E-42F1-9951-3313B3E43779Q41144790-2BDA8957-2B41-4C69-970D-8A8E3100B715Q41416491-8515032B-B41E-441A-8DCD-A57637CB4864Q41708999-25BE9378-6B4D-4712-B4CD-E8388C75C473Q41808513-81AEEE64-6AB9-4D35-B91C-B17A116B4F00Q44442164-65431CC4-573F-4E34-8D6F-3981FE16AD63
P2860
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Safety and anti-tumor activity ...... : a review of clinical trials.
@en
Safety and anti-tumor activity of sorafenib
@nl
type
label
Safety and anti-tumor activity ...... : a review of clinical trials.
@en
Safety and anti-tumor activity of sorafenib
@nl
prefLabel
Safety and anti-tumor activity ...... : a review of clinical trials.
@en
Safety and anti-tumor activity of sorafenib
@nl
P1476
Safety and anti-tumor activity ...... : a review of clinical trials.
@en
P2093
Ahmad Awada
Chris H Takimoto
P2860
P2888
P304
P356
10.1007/S00280-007-0639-9
P577
2007-11-17T00:00:00Z